- Home
- FOA vs LUNG Comparison
FOA vs LUNG Comparison
Compare FOA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- LUNG
- Stock Information
- Founded
- FOA 2013
- LUNG 1995
- Country
- FOA United States
- LUNG United States
- Employees
- FOA N/A
- LUNG N/A
- Industry
- FOA Finance Companies
- LUNG Industrial Specialties
- Sector
- FOA Finance
- LUNG Health Care
- Exchange
- FOA Nasdaq
- LUNG Nasdaq
- Market Cap
- FOA 240.8M
- LUNG 256.3M
- IPO Year
- FOA N/A
- LUNG 2020
- Fundamental
- Price
- FOA $26.42
- LUNG $6.34
- Analyst Decision
- FOA Hold
- LUNG Buy
- Analyst Count
- FOA 1
- LUNG 6
- Target Price
- FOA $24.00
- LUNG $11.92
- AVG Volume (30 Days)
- FOA 222.7K
- LUNG 214.3K
- Earning Date
- FOA 03-05-2025
- LUNG 02-19-2025
- Dividend Yield
- FOA N/A
- LUNG N/A
- EPS Growth
- FOA N/A
- LUNG N/A
- EPS
- FOA 10.89
- LUNG N/A
- Revenue
- FOA $719,526,000.00
- LUNG $79,302,000.00
- Revenue This Year
- FOA N/A
- LUNG $22.26
- Revenue Next Year
- FOA N/A
- LUNG $18.72
- P/E Ratio
- FOA $2.51
- LUNG N/A
- Revenue Growth
- FOA 3011.46
- LUNG 22.34
- 52 Week Low
- FOA $4.10
- LUNG $5.46
- 52 Week High
- FOA $32.40
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- FOA 53.66
- LUNG 41.35
- Support Level
- FOA $24.01
- LUNG $6.24
- Resistance Level
- FOA $27.93
- LUNG $7.27
- Average True Range (ATR)
- FOA 2.61
- LUNG 0.39
- MACD
- FOA -0.49
- LUNG -0.06
- Stochastic Oscillator
- FOA 40.32
- LUNG 2.52
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.